NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 174)
Posted On: 09/28/2022 3:58:43 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) to Focus on Launch of Proprietary UST Processing Method in Emerging Growth Conference Presentation
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is presenting at today’s Emerging Growth Investor Conference. The conference has built a reputation for being an effective way for publicly traded companies to present and communicate new products and services as well as other major announcements to thousands of individual and institutional investors and investment advisors and analysts. PBI president and CEO Richard T. Schumacher spoke at 9 a.m. ET; the focus of his presentation was on the much-anticipated commercial launch of the company’s Ultra Shear Technology(TM) (“UST”) nanoemulsification platform. Throughout the past few months, Pressure BioSciences has entered three agreements covering the production, distribution, commercial roll-out and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use; the company also has entered a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with more than $500 million in QVC sales. “All four contracts are based on the use of the UST platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics,” the company stated in the press release. “Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, astaxanthin, curcumin, retinol, prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The company plans to close on a minimum of six additional contracts over the remaining months of FY 2022, further adding to 2023 revenue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide life sciences, nutraceuticals, cosmetics, food and beverage, and other key industries, is presenting at today’s Emerging Growth Investor Conference. The conference has built a reputation for being an effective way for publicly traded companies to present and communicate new products and services as well as other major announcements to thousands of individual and institutional investors and investment advisors and analysts. PBI president and CEO Richard T. Schumacher spoke at 9 a.m. ET; the focus of his presentation was on the much-anticipated commercial launch of the company’s Ultra Shear Technology(TM) (“UST”) nanoemulsification platform. Throughout the past few months, Pressure BioSciences has entered three agreements covering the production, distribution, commercial roll-out and financial partnership for novel, effectively water-soluble, highly bioavailable, nanoemulsified CBD products for both oral and topical use; the company also has entered a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-year skincare industry leader with more than $500 million in QVC sales. “All four contracts are based on the use of the UST platform to develop nanoemulsions of oil-based nutraceuticals and cosmetics,” the company stated in the press release. “Nanoemulsions are known to turn oil-based active ingredient mixtures (e.g., CBD, THC, astaxanthin, curcumin, retinol, prednisone) into long-term stable, effectively water-soluble, highly bioavailable formulations. The company believes these four contracts alone could generate over $5 million of accretive revenue for PBI in 2023. The company plans to close on a minimum of six additional contracts over the remaining months of FY 2022, further adding to 2023 revenue.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼